Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Phase 1

Terminated

• Conditions: Cutaneous Lupus; Discoid Lupus; Lupus; Systemic Lupus Erythematosus
• Interventions: Drug: AMG811; Drug: AMG811 Placebo

• Registration Number: NCT01164917
• Lead Sponsor: Amgen

Brief Summary

This is a multi-center, randomized, double-blind, placebo-controlled, two-period, crossover study in which approximately 20 subjects with Discoid Lupus Erythematosus will be enrolled to receive AMG 811 and placebo in one of two sequences (ie, AMG 811 followed by placebo or placebo followed by AMG 811).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-07-15
• Study First Submitted QC: 2010-07-15
• Study First Posted: 2010-07-19
• Study Start: 2010-08
• Primary Completion: 2012-09
• Study Completion: 2013-03
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-12
• Last Update Posted: 2014-09-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Men and women, between the ages of 18 and 70 years of age, inclusive, at the time of randomization;
• Diagnosis of discoid lupus erythematosus (DLE) with or without SLE;
• Intolerance of anti-malarial therapy or ≥ 3 months of anti-malarial therapy with residual disease activity. The total CLASI activity must be ≥ 10;
• Stable dose of topical steroids no stronger than medium-potency (Class III or less) for ≥ 2 weeks and/or systemic immunosuppressive therapy at stable dose for ≥ 8 weeks prior to randomization (except for leflunomide which requires ≥ 12 weeks) are permitted;
• Oral prednisone ≤ 20 mg/day (or equivalent) is permitted; one increase or one decrease of ≤ 5 mg/day prednisone equivalent (not to exceed 20 mg/day) will be allowed within 30 days before randomization;

Exclusion Criteria

• Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of DLE or SLE) that would, by its progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures per the investigator's discretion;
• History of malignancy;
• Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections;
• Subjects with evidence of past or active tuberculosis
• Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies (confirmed by PCR or RIBA) during the screening period;
• Receipt of a live vaccine within 3 months of study randomization and during the study;
• Prior use of the following agents:
• Administration of an investigational biologic agent that primarily targets the immune system -
• Rituximab, Lymphostat-B, or TACl-Ig within 9 months prior to randomization (or comparable B cell depleting or B cell inhibiting biologics); Rituximab (or other depleting CD20 targeted agents) treated patients must demonstrate a return of CD19+ B cells to > 5/μL;
• CTLA4-Ig within 3 months prior to randomization;
• Other agents within 5 half-lives prior to randomization;
• Administration of cyclosporine, tacrolimus, sirolimus, IV immunoglobulin, and/or plasmapheresis within 3 months of randomization;
• Administration of thalidomide or lenalidomide within 3 months of randomization;
• Administration of oral or IV cyclophosphamide (or any other alkylating agent) within 9 months of randomization;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AMG811	AMG811	All will receive AMG 811, either on Day 1 or Day 85
AMG811 Placebo	AMG811 Placebo	All will receive placebo, either on Day 1 or Day 85

Primary Outcome Measures

Name	Time	Method
Safety evaluation: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examination endpoints, clinical laboratory safety tests, ECGs and the development of anti-AMG811 antibodies	197 days

Secondary Outcome Measures

Name	Time	Method
PK parameters, Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and IFN-gamma related gene expression in skin biopsy samples	197 days

Trial Locations

Locations (1)

Research Site; 🇺🇸 Salt Lake City, Utah, United States